Sunday, October 11, 2026

Roku Stock Is 5.61% Up So Far On Monday

ViaNews Editorial Team

November 23, 2020

Roku Stock Is 5.61% Up So Far On Monday

Roku has been somewhat immune to the crisis with its shares rising 5.61% to $277.90 at 11:10 EST on Monday, after two sequential sessions in a row of gains. The Nasdaq Stock Market is falling 0.1% to $11,842.60, following yesterday's downward trend, on what as yet seems, a somewhat rough trend trading session on today.

Roku's last close was $263.14, under its 52-week high of $275.90.

Roku's sales growth is 46.1% for the ongoing quarter and 41.5% for the next. The company's growth estimates for the ongoing quarter and the next is 30.8% and 26.7%, respectively.

Year-on-year quarterly revenue growth grew by 73.1%, now sitting on 1.54B for the twelve trailing months.

Roku's stock is valued at $277.90 at 11:10 EST, above its 52-week high of $275.90.

Roku's worth is way above its 50-day moving average of $224.48 and way above its 200-day moving average of $164.07.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com